BioAtla BCAB
NASDAQ BCAB
$1.40 +0.08 (+6.06%)
At close: Sep 8, 2026 · 4:00 PM EDT

BioAtla (BCAB) Assets Average (2021 - 2026)

BioAtla's (BCAB) quarterly Assets Average came in at $9.0 million in Q2 2026, down 72.37% on a YoY basis from $32.7 million in Q2 2025, and down 19.3% quarter-over-quarter from $11.2 million in Q1 2026.

Analysis

BioAtla (BCAB) Assets Average (2021 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Assets Average for 6 consecutive years, with $9.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Assets Average fell 72.37% year-over-year to $9.0 million; the trailing twelve-month figure through Jun 2026 stood at $9.0 million (down 72.37% YoY), and the FY2025 full-year result was $33.1 million, down 61.5% from the prior year.
  • Assets Average slipped to $9.0 million in Q2 2026 per BCAB's latest filing, from $11.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $242.5 million in Q1 2022 and bottomed at $9.0 million in Q2 2026.
  • Historically, Assets Average has averaged $112.4 million across 5 years, with a median of $91.7 million in 2024.
  • The sharpest annual moves came in 2022 and 2026: Assets Average grew 2.33% in 2022, then sank 75.31% in 2026.
  • Over 5 years, Assets Average stood at $207.4 million in 2022, then tumbled by 34.67% to $135.5 million in 2023, then tumbled by 57.69% to $57.3 million in 2024, then slumped by 74.07% to $14.9 million in 2025, then plunged by 39.23% to $9.0 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods registered $9.0 million, $11.2 million, and $14.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Amgen 207.17 Bn 193.18 Bn 7.24 Bn 94.07 Bn
2 Gilead Sciences 179.52 Bn 176.34 Bn 6.22 Bn 52.82 Bn
3 Vertex Pharmaceuticals 131.47 Bn 123.62 Bn 2.84 Bn 26.95 Bn
4 Regeneron Pharmaceuticals 81.73 Bn 73.74 Bn 3.93 Bn 41.30 Bn
5 Argenx Se 61.16 Bn 55.98 Bn 1.37 Bn -
6 Moderna 53.28 Bn 48.14 Bn 52.00 Mn 11.22 Bn
7 Alnylam Pharmaceuticals 33.06 Bn 29.76 Bn 992.69 Mn 5.34 Bn
8 Biogen 31.65 Bn 30.37 Bn 1.96 Bn 30.78 Bn
9 Roivant Sciences 29.30 Bn 29.30 Bn 1.16 Mn 5.51 Bn
10 BioAtla 2.33 Mn 2.33 Mn - 9.04 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.04 Mn
Mar 31, 2026 11.20 Mn
Dec 31, 2025 14.87 Mn
Sep 30, 2025 21.52 Mn
Jun 30, 2025 32.71 Mn
Mar 31, 2025 45.36 Mn
Dec 31, 2024 57.33 Mn
Sep 30, 2024 65.44 Mn
Jun 30, 2024 78.92 Mn
Mar 31, 2024 104.43 Mn
Dec 31, 2023 135.51 Mn
Sep 30, 2023 165.50 Mn
Jun 30, 2023 192.09 Mn
Mar 31, 2023 215.14 Mn
Dec 31, 2022 207.42 Mn
Sep 30, 2022 201.30 Mn
Jun 30, 2022 222.07 Mn
Mar 31, 2022 242.54 Mn
Dec 31, 2021 266.00 Mn
Sep 30, 2021 247.14 Mn